Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
62
IMDX Quote, Financials, Valuation and Earnings
Last price:
$6.51
Seasonality move
:
9.95%
Day range:
$6.04 - $6.74
52-week range:
$1.95 - $8.51
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
39.67x
P/B ratio:
196.14x
Volume:
39.9K
Avg. volume:
38K
1-year change:
224.38%
Market cap:
$186.9M
Revenue:
$1.9M
EPS (TTM):
-$2.83
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$285K | -$0.23 | -80.82% | -75.61% | $7.00 |
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
PRPH
ProPhase Labs, Inc.
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
VCYT
Veracyte, Inc.
|
$134.5M | $0.40 | 14.28% | 278.39% | $47.67 |
|
XGN
Exagen, Inc.
|
$16.9M | -$0.18 | 13.89% | -20.87% | $14.71 |
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics, Inc.
|
$6.52 | $7.00 | $186.9M | -- | $0.00 | 0% | 39.67x |
|
FONR
FONAR Corp.
|
$18.61 | -- | $117.2M | 16.82x | $0.00 | 0% | 1.13x |
|
PRPH
ProPhase Labs, Inc.
|
$0.36 | $13.80 | $1.5M | -- | $0.00 | 0% | 0.25x |
|
VCYT
Veracyte, Inc.
|
$42.27 | $47.67 | $3.3B | 111.35x | $0.00 | 0% | 6.79x |
|
XGN
Exagen, Inc.
|
$4.60 | $14.71 | $104.3M | -- | $0.00 | 0% | 1.46x |
|
XWEL
XWELL, Inc.
|
$0.35 | -- | $2M | -- | $0.00 | 0% | 0.06x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-51.52% | -0.710 | 3.29% | 2.57x |
|
FONR
FONAR Corp.
|
18.59% | 1.184 | 49.09% | 9.64x |
|
PRPH
ProPhase Labs, Inc.
|
52.83% | 0.697 | 40.4% | 0.07x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.309 | 1.49% | 5.74x |
|
XGN
Exagen, Inc.
|
60.83% | 0.343 | 11.39% | 3.63x |
|
XWEL
XWELL, Inc.
|
278.04% | 2.325 | 65.46% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IMDX
Insight Molecular Diagnostics, Inc.
|
-$423K | -$7.7M | -1767.73% | -1008.03% | -2950% | -$5.6M |
|
FONR
FONAR Corp.
|
$10.4M | $3.2M | 4.68% | 5.84% | 12.26% | -$636K |
|
PRPH
ProPhase Labs, Inc.
|
-$650.5K | -$4.8M | -51.85% | -90.24% | -539.52% | -$3.5M |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
|
XGN
Exagen, Inc.
|
$10.1M | -$3.1M | -49.66% | -140.03% | -17.98% | $2.7M |
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
Insight Molecular Diagnostics, Inc. vs. Competitors
-
Which has Higher Returns IMDX or FONR?
FONAR Corp. has a net margin of -4174.62% compared to Insight Molecular Diagnostics, Inc.'s net margin of 10.25%. Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03% beat FONAR Corp.'s return on equity of 5.84%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M FONRFONAR Corp.40.11% $0.34 $201.3M -
What do Analysts Say About IMDX or FONR?
Insight Molecular Diagnostics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 7.36%. On the other hand FONAR Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Insight Molecular Diagnostics, Inc. has higher upside potential than FONAR Corp., analysts believe Insight Molecular Diagnostics, Inc. is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics, Inc.1 2 0 FONRFONAR Corp.0 0 0 -
Is IMDX or FONR More Risky?
Insight Molecular Diagnostics, Inc. has a beta of 1.109, which suggesting that the stock is 10.885% more volatile than S&P 500. In comparison FONAR Corp. has a beta of 0.993, suggesting its less volatile than the S&P 500 by 0.67700000000001%.
-
Which is a Better Dividend Stock IMDX or FONR?
Insight Molecular Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FONAR Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics, Inc. pays -- of its earnings as a dividend. FONAR Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or FONR?
Insight Molecular Diagnostics, Inc. quarterly revenues are $260K, which are smaller than FONAR Corp. quarterly revenues of $26M. Insight Molecular Diagnostics, Inc.'s net income of -$10.9M is lower than FONAR Corp.'s net income of $2.7M. Notably, Insight Molecular Diagnostics, Inc.'s price-to-earnings ratio is -- while FONAR Corp.'s PE ratio is 16.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics, Inc. is 39.67x versus 1.13x for FONAR Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics, Inc.39.67x -- $260K -$10.9M FONRFONAR Corp.1.13x 16.82x $26M $2.7M
-
Which has Higher Returns IMDX or PRPH?
ProPhase Labs, Inc. has a net margin of -4174.62% compared to Insight Molecular Diagnostics, Inc.'s net margin of -774.52%. Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03% beat ProPhase Labs, Inc.'s return on equity of -90.24%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M -
What do Analysts Say About IMDX or PRPH?
Insight Molecular Diagnostics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 7.36%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 37958.47%. Given that ProPhase Labs, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe ProPhase Labs, Inc. is more attractive than Insight Molecular Diagnostics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics, Inc.1 2 0 PRPHProPhase Labs, Inc.0 0 0 -
Is IMDX or PRPH More Risky?
Insight Molecular Diagnostics, Inc. has a beta of 1.109, which suggesting that the stock is 10.885% more volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.559, suggesting its less volatile than the S&P 500 by 155.946%.
-
Which is a Better Dividend Stock IMDX or PRPH?
Insight Molecular Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics, Inc. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or PRPH?
Insight Molecular Diagnostics, Inc. quarterly revenues are $260K, which are smaller than ProPhase Labs, Inc. quarterly revenues of $883K. Insight Molecular Diagnostics, Inc.'s net income of -$10.9M is lower than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, Insight Molecular Diagnostics, Inc.'s price-to-earnings ratio is -- while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics, Inc. is 39.67x versus 0.25x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics, Inc.39.67x -- $260K -$10.9M PRPHProPhase Labs, Inc.0.25x -- $883K -$6.8M
-
Which has Higher Returns IMDX or VCYT?
Veracyte, Inc. has a net margin of -4174.62% compared to Insight Molecular Diagnostics, Inc.'s net margin of 14.51%. Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03% beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About IMDX or VCYT?
Insight Molecular Diagnostics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 7.36%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.67 which suggests that it could grow by 12.77%. Given that Veracyte, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe Veracyte, Inc. is more attractive than Insight Molecular Diagnostics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics, Inc.1 2 0 VCYTVeracyte, Inc.8 2 1 -
Is IMDX or VCYT More Risky?
Insight Molecular Diagnostics, Inc. has a beta of 1.109, which suggesting that the stock is 10.885% more volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.569%.
-
Which is a Better Dividend Stock IMDX or VCYT?
Insight Molecular Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics, Inc. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or VCYT?
Insight Molecular Diagnostics, Inc. quarterly revenues are $260K, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. Insight Molecular Diagnostics, Inc.'s net income of -$10.9M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, Insight Molecular Diagnostics, Inc.'s price-to-earnings ratio is -- while Veracyte, Inc.'s PE ratio is 111.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics, Inc. is 39.67x versus 6.79x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics, Inc.39.67x -- $260K -$10.9M VCYTVeracyte, Inc.6.79x 111.35x $131.9M $19.1M
-
Which has Higher Returns IMDX or XGN?
Exagen, Inc. has a net margin of -4174.62% compared to Insight Molecular Diagnostics, Inc.'s net margin of -41.1%. Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03% beat Exagen, Inc.'s return on equity of -140.03%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M XGNExagen, Inc.58.43% -$0.31 $46.3M -
What do Analysts Say About IMDX or XGN?
Insight Molecular Diagnostics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 7.36%. On the other hand Exagen, Inc. has an analysts' consensus of $14.71 which suggests that it could grow by 219.88%. Given that Exagen, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe Exagen, Inc. is more attractive than Insight Molecular Diagnostics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics, Inc.1 2 0 XGNExagen, Inc.8 0 0 -
Is IMDX or XGN More Risky?
Insight Molecular Diagnostics, Inc. has a beta of 1.109, which suggesting that the stock is 10.885% more volatile than S&P 500. In comparison Exagen, Inc. has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.324%.
-
Which is a Better Dividend Stock IMDX or XGN?
Insight Molecular Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exagen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics, Inc. pays -- of its earnings as a dividend. Exagen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or XGN?
Insight Molecular Diagnostics, Inc. quarterly revenues are $260K, which are smaller than Exagen, Inc. quarterly revenues of $17.2M. Insight Molecular Diagnostics, Inc.'s net income of -$10.9M is lower than Exagen, Inc.'s net income of -$7.1M. Notably, Insight Molecular Diagnostics, Inc.'s price-to-earnings ratio is -- while Exagen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics, Inc. is 39.67x versus 1.46x for Exagen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics, Inc.39.67x -- $260K -$10.9M XGNExagen, Inc.1.46x -- $17.2M -$7.1M
-
Which has Higher Returns IMDX or XWEL?
XWELL, Inc. has a net margin of -4174.62% compared to Insight Molecular Diagnostics, Inc.'s net margin of -2.87%. Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03% beat XWELL, Inc.'s return on equity of -224.93%.
Company Gross Margin Earnings Per Share Invested Capital IMDXInsight Molecular Diagnostics, Inc.-162.69% -$0.34 -$6.1M XWELXWELL, Inc.17.32% -$0.26 $13M -
What do Analysts Say About IMDX or XWEL?
Insight Molecular Diagnostics, Inc. has a consensus price target of $7.00, signalling upside risk potential of 7.36%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 1927.81%. Given that XWELL, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe XWELL, Inc. is more attractive than Insight Molecular Diagnostics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IMDXInsight Molecular Diagnostics, Inc.1 2 0 XWELXWELL, Inc.0 0 0 -
Is IMDX or XWEL More Risky?
Insight Molecular Diagnostics, Inc. has a beta of 1.109, which suggesting that the stock is 10.885% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.326, suggesting its more volatile than the S&P 500 by 32.585%.
-
Which is a Better Dividend Stock IMDX or XWEL?
Insight Molecular Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insight Molecular Diagnostics, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IMDX or XWEL?
Insight Molecular Diagnostics, Inc. quarterly revenues are $260K, which are smaller than XWELL, Inc. quarterly revenues of $7.3M. Insight Molecular Diagnostics, Inc.'s net income of -$10.9M is lower than XWELL, Inc.'s net income of -$211K. Notably, Insight Molecular Diagnostics, Inc.'s price-to-earnings ratio is -- while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insight Molecular Diagnostics, Inc. is 39.67x versus 0.06x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IMDXInsight Molecular Diagnostics, Inc.39.67x -- $260K -$10.9M XWELXWELL, Inc.0.06x -- $7.3M -$211K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
47
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
56
INTC alert for Jan 24
Intel Corp. [INTC] is down 17.01% over the past day.
Buy
64
BNR alert for Jan 24
Burning Rock Biotech Ltd. [BNR] is down 12.81% over the past day.
Sell
19
APGE alert for Jan 24
Apogee Therapeutics, Inc. [APGE] is down 12.28% over the past day.
